1. Home
  2. UCL vs BLRX Comparison

UCL vs BLRX Comparison

Compare UCL & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo uCloudlink Group Inc.

UCL

uCloudlink Group Inc.

HOLD

Current Price

$1.01

Market Cap

40.0M

ML Signal

HOLD

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

HOLD

Current Price

$3.66

Market Cap

12.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UCL
BLRX
Founded
2014
2003
Country
Hong Kong
Israel
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.0M
12.6M
IPO Year
2019
2010

Fundamental Metrics

Financial Performance
Metric
UCL
BLRX
Price
$1.01
$3.66
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$19.00
AVG Volume (30 Days)
9.4K
44.6K
Earning Date
05-20-2026
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$11.60
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.72
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.95
$2.15
52 Week High
$4.19
$6.59

Technical Indicators

Market Signals
Indicator
UCL
BLRX
Relative Strength Index (RSI) 35.51 67.08
Support Level N/A $3.48
Resistance Level $1.19 $3.93
Average True Range (ATR) 0.08 0.26
MACD 0.01 0.05
Stochastic Oscillator 33.33 75.18

Price Performance

Historical Comparison
UCL
BLRX

About UCL uCloudlink Group Inc.

Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data-related products globally. Its uCloudlink cloud SIM platform is designed for shared mobile data connectivity services by allocating the SIM cards remotely and dynamically to users. Ucloudlink's core business is to provide mobile data connectivity services at competitive prices, which it delivers through a range of hardware products and service solutions to its business partners, retail, and enterprise customers. The main hardware terminals offered by the company include portable Wi-Fi terminals, smartphones, and smart-hardware products for international and local mobile data connectivity services. Geographically, it generates maximum revenue from Japan.

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: